guest ::
| Home > Publications database > Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin > print |
| Home > Publications database > Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin > print |
| 001 | 481559 | ||
| 005 | 20250724151718.0 | ||
| 024 | 7 | _ | |a 10.1021/acs.jmedchem.2c00904 |2 doi |
| 024 | 7 | _ | |a 0022-2623 |2 ISSN |
| 024 | 7 | _ | |a 0095-9065 |2 ISSN |
| 024 | 7 | _ | |a 1520-4804 |2 ISSN |
| 024 | 7 | _ | |a 1943-2992 |2 ISSN |
| 024 | 7 | _ | |a 10.3204/PUBDB-2022-04452 |2 datacite_doi |
| 024 | 7 | _ | |a altmetric:132684419 |2 altmetric |
| 024 | 7 | _ | |a pmid:35833347 |2 pmid |
| 024 | 7 | _ | |a WOS:000830067600001 |2 WOS |
| 024 | 7 | _ | |a openalex:W4285388169 |2 openalex |
| 037 | _ | _ | |a PUBDB-2022-04452 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Vourloumis, Dionisios |b 0 |
| 245 | _ | _ | |a Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin |
| 260 | _ | _ | |a Washington, DC |c 2022 |b ACS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1661417694_3324 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The oxytocinase subfamily of M1 zinc aminopeptidases comprises emerging drug targets, including the ER-resident aminopeptidases 1 and 2 (ERAP1 and ERAP2) and insulin-regulated aminopeptidase (IRAP); however, reports on clinically relevant inhibitors are limited. Here we report a new synthetic approach of high diastereo- and regioselectivity for functionalization of the α-hydroxy-β-amino acid scaffold of bestatin. Stereochemistry and mechanism of inhibition were investigated by a high-resolution X-ray crystal structure of ERAP1 in complex with a micromolar inhibitor. By exploring the P1 side-chain functionalities, we achieve significant potency and selectivity, and we report a cell-active, low-nanomolar inhibitor of IRAP with >120-fold selectivity over homologous enzymes. X-ray crystallographic analysis of IRAP in complex with this inhibitor suggest that interactions with the GAMEN loop is an unappreciated key determinant for potency and selectivity. Overall, our results suggest that α-hydroxy-β-amino acid derivatives may constitute useful chemical tools and drug leads for this group of aminopeptidases. |
| 536 | _ | _ | |a 6G3 - PETRA III (DESY) (POF4-6G3) |0 G:(DE-HGF)POF4-6G3 |c POF4-6G3 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: bib-pubdb1.desy.de |
| 693 | _ | _ | |a PETRA III |f PETRA Beamline P13 |1 EXP:(DE-H253)PETRAIII-20150101 |0 EXP:(DE-H253)P-P13-20150101 |6 EXP:(DE-H253)P-P13-20150101 |x 0 |
| 700 | 1 | _ | |a Mavridis, Ioannis |b 1 |
| 700 | 1 | _ | |a Athanasoulis, Alexandros |b 2 |
| 700 | 1 | _ | |a Temponeras, Ioannis |b 3 |
| 700 | 1 | _ | |a Koumantou, Despoina |b 4 |
| 700 | 1 | _ | |a Giastas, Petros |b 5 |
| 700 | 1 | _ | |a Mpakali, Anastasia |0 0000-0003-0869-9680 |b 6 |
| 700 | 1 | _ | |a Magrioti, Victoria |b 7 |
| 700 | 1 | _ | |a Leib, Jacqueline |b 8 |
| 700 | 1 | _ | |a van Endert, Peter |b 9 |
| 700 | 1 | _ | |a Stratikos, Efstratios |0 P:(DE-HGF)0 |b 10 |e Corresponding author |
| 700 | 1 | _ | |a Papakyriakou, Athanasios |0 P:(DE-HGF)0 |b 11 |e Corresponding author |
| 773 | _ | _ | |a 10.1021/acs.jmedchem.2c00904 |g Vol. 65, no. 14, p. 10098 - 10117 |0 PERI:(DE-600)1491411-6 |n 14 |p 10098 - 10117 |t Journal of medicinal chemistry |v 65 |y 2022 |x 0022-2623 |
| 856 | 4 | _ | |u https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c00904 |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/481559/files/Discovery%20of%20Selective%20Nanomolar%20Inhibitors%20for%20Insulin%20Regulated%20Aminopeptidase%20Based%20on%20a%20Hydroxy%20b%20amino%20Acid%20Derivatives%20of%20Bestatin.pdf |y Restricted |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/481559/files/document.pdf |y Published on 2022-07-14. Available in OpenAccess from 2023-07-14. |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/481559/files/Discovery%20of%20Selective%20Nanomolar%20Inhibitors%20for%20Insulin%20Regulated%20Aminopeptidase%20Based%20on%20a%20Hydroxy%20b%20amino%20Acid%20Derivatives%20of%20Bestatin.pdf?subformat=pdfa |x pdfa |y Restricted |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/481559/files/document.pdf?subformat=pdfa |x pdfa |y Published on 2022-07-14. Available in OpenAccess from 2023-07-14. |
| 909 | C | O | |o oai:bib-pubdb1.desy.de:481559 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Materie |l Großgeräte: Materie |1 G:(DE-HGF)POF4-6G0 |0 G:(DE-HGF)POF4-6G3 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-600 |4 G:(DE-HGF)POF |v PETRA III (DESY) |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-30 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1200 |2 StatID |b Chemical Reactions |d 2021-01-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J MED CHEM : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1210 |2 StatID |b Index Chemicus |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J MED CHEM : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-30 |
| 920 | 1 | _ | |0 I:(DE-H253)EMBL-User-20120814 |k EMBL-User |l EMBL-User |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-H253)EMBL-User-20120814 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|